SciSparc subsidiary NeuroThera expands U.S. patent filings with Clearmind for PEA combinations with LSD, ketamine, ibogaine
SPRC•NeuroThera flags three U.S. patent applications
- SciSparc subsidiary NeuroThera flagged three published U.S. patent applications with Clearmind covering PEA combinations with LSD, ketamine, ibogaine.
- Filings target potential treatments for depression, PTSD, pain, substance use disorders, expanding NeuroThera’s U.S. intellectual property portfolio.
- Collaboration previously generated a U.S. patent application covering MDMA combined with N-acylethanolamines for PTSD, anxiety, eating disorders.
